Transcript Slide 1

Stephen Cohn, MD, FACS, UTHSC-SA
SELECTING RESEARCH
PRIORITIES AND STUDIES
NTI Science Committee
 Subject matter experts
 Senior leadership
 In-depth knowledge/awareness of prior
and current trauma research
 Members:
Peggy Knudson, MD, Chair
Ellen J. MacKenzie, PhD
David B. Hoyt, MD, Vice-Chair
Andrew B. Peitzman, MD
Timothy C. Fabian, MD
Basil A. Pruitt, Jr., MD
Donald H. Jenkins, MD
Ronald M. Stewart, MD
Gregory J. Jurkovich, MD
Science Committee Role
 Determines priorities for each RFP, which is then
broadly distributed
 Reviews pre-proposals and issues invitations for full
proposals
 Evaluates proposals, makes proposal selections,
and recommends awards and funding decisions to
the Board
 The Board, which includes representatives of Army,
Air Force, and Navy, considers recommendations
for full approval
3
Review Criteria
 Scientific merit
 Clinical relevance
 Clinical impact
 Innovation
 Feasibility of completing study on time
 Military relevance
 Appropriate budget
 Potential for follow-on studies
 Multicenter involvement
Proposals and Awards
 April, 2010
 85 pre-proposals from 25 states plus DC
 15 invitations for full proposals
 7 awarded studies, with 22 participating sites
 January, 2011
 92 pre-proposals from 25 states
 21 invitations for full proposals
 8 awarded studies, with 20 participating sites
5
Pre-proposal Response
Award Distribution
16 Lead Sites
42 Participating Sites
NTI Awarded Studies
$3.8 million
 Mycoplasma Pneumoniae in the ICU
 Dr. Joel Baseman, University of Texas Health Science Center at San Antonio
 Timing and Mechanism of Traumatic Coagulopathy
 Dr. Mitchell Cohen, University of California at San Francisco
 Evaluation of Ventilator Bundle in Injured Patients
 Dr. Martin Croce, University of Tennessee Health Science Center at Memphis
 Comparative Effectiveness of Clinical Care Processes in
Resuscitation and Management of Moderate to Severe
Traumatic Injuries
 Dr. Shahid Shafi, Baylor Research Institute
 Comparison of IV Iron Supplementation to both Enteral
Supplementation and Placebo for the Anemia of Traumatic
Critical Illness
 Dr. Fred Pieracci, University of Colorado at Denver
8
 Vasopressin Supplementation during Resuscitation of
Hemorrhagic Shock
 Dr. Carrie Sims, University of Pennsylvania
 Characterization of the effects of the early Sex-Hormone
Environment Following Injury
 Dr. Jason Sperry, University of Pittsburgh
 The Safety and Efficacy of Platelet Transfusion in Patients
Receiving Antiplatelet Therapy that Sustain Intracranial
Hemorrhage
 Mark Cipolle, Christiana Health Care System, Newark DE
 Effect of Antioxidant Vitamins on Coagulopathy and
Nosocomial Pneumonia after Severe Trauma
 Jean-Francois Pittet, University of Alabama at Birmingham
 Detection and Management of Non-Compressible
Hemorrhage by Vena Cava Ultrasonography
 Jay J Doucet, University of California San Diego
9
 Splenic Injury Prospective Outcomes Trial
 Ben Zarzaur, AAST/ PI: University of Tennessee Health Science Center,
Memphis TN
 Transfusion of Stored Fresh Whole Blood in a Civilian Trauma
Center: A Prospective Evaluation of Feasibility and
Outcomes
 Gill Cryer, UCLA Dept of Surgery, Los Angeles, CA
 Acute Lung Injury Ventilation Evaluation (ALIVE) Trial
 Suresh Agarwal, Boston Medical Center, Boston, MA
 Methicillin-Resistant Staphylococcus aureus in a Trauma
Population: Does Decolonization Prevent Infection?
 Robert Maxwell, Univ. of Tenn. HSC, Chattanooga, TN
 Thrombelastography (TEG®) based dosing of enoxaparin for
thromboprophylaxis: a prospective randomized trial
 Martin A Schreiber, Oregon Health & Science University, Portland, OR
 Hepcidin and Anemia in Trauma
 Lena M. Napolitano, Univ. of Michigan Health System, Ann Arbor MI
Research Project Awards:
NTI Role/Responsibilities
 Manages RFP and review process
 Manages regulatory compliance through TATRC,
HRPO, and USAMRMC
 Manages contracts
 Monitors scientific progress and prepares reports
 Holds annual investigator meeting
 Sponsors annual trauma conference to disseminate
results, encourage investigators, and support
military/civilian exchange
11

Timing and Mechanism of Traumatic Coagulopathy
 Wireless Vital Sign Monitor Project
 Mycoplasma Pneumoniae in the ICU
SELECT NTI FUNDED STUDIES
Stephen Cohn, MD, FACS, UTHSC-SA
MYCOPLASMA PNEUMONIAE IN
THE ICU
Mycoplasma Pneumoniae in the ICU
 Preliminary data showed M. pneumoniae
 common in ICU patients with suspected VAP
 associated with prolonged ventilator course
 associated with poor oxygenation in subjects with
ARDS
14
Mycoplasma Pneumoniae in the ICU
 Multicenter, prospective, observational study
 Investigating the role of Mycoplasma
pneumoniae in ICU patients with suspected
ventilator-associated pneumonia (VAP)
 Objectives are to:
 determine the incidence of M. pneumoniae infection
among critically ill ventilator-dependent subjects
 evaluate the impact of this pathogen on ICU
outcomes
15
Mycoplasma Pneumoniae in the ICU
 Apply novel diagnostic assays targeting the Community






Acquired Respiratory Distress Syndrome (CARDS) toxin
Subjects undergo routine bronchoscopy with
bronchoalveolar lavage (BAL) for the diagnosis of VAP
Samples of BAL fluid and serum collected
Polymerase chain reaction (PCR) assessment for CARDS
toxin gene sequences
BAL tested for CARDS toxin protein
Serum assayed for anti-CARDS toxin antibodies
Additional serum samples collected to test for
seroconversion
16
Mycoplasma Pneumoniae in the ICU
 Research will:
 Determine the incidence of M. pneumoniae
 Determine the ventilator course and ICU outcomes
 Determine the physiologic implications of M.
pneumoniae in this setting
 Expand upon preliminary findings from a single
hospital
17
Mycoplasma Pneumoniae in the ICU
 First study to employ these novel assays for the
rapid detection of M. pneumoniae infection in
the ICU
 First study to systematically evaluate the
contribution of this pathogen to pulmonary
dysfunction in critically ill subjects.
18